Patient Oriented Therapy for STE-MI Seçkin Pehlivanoğlu, MD Başkent University, İstanbul Hospital.
Should we use bivalirudin ? Fibrin 2 1 Thrombin 2 1 Thrombin 2 1 Trombina 2 1 Trombina Bivalirudin ADVANTAGES - No requirement for anti-thrombin III -
Invasiv behandling af hjertepatienten med diabetes AstraZenecas 32. kardiovaskulære årsmøde Kolding 23.-24. januar 2009 Hans Erik Bøtker.
La preparazione alla PCI nelle SCA Razionale allimpiego degli antiaggreganti e degli anticoagulanti Firenze, 23 gennaio 2010 Maddalena Lettino Fondazione.
Local improvement following national clinical audit workshops Auditing heart attacks Saving lives Dr Andrew Wragg Barts Health.
“Should I add a PPI?” A review of inpatient GI prophylaxis Lenny Noronha, MD Associate Professor, Hospitalist Section 2/5/10.
Neeral L. Shah, M.D., F.A.C.P Assistant Professor of Medicine Division of Gastroenterology and Hepatology Transplant Clinic Director GI Clinical Pearls.
Vascular Pharmacology Phil Copeman and Alex Hammant.
Drugs used in coagulation disorders By S.Bohlooli, Ph.D.
GUSTO I 90-93 GUSTO I 90-93 2.8 Median Time (hrs) Between Symptom Onset and Treatment GUSTO III 95-97 GUSTO III 95-97 InTIME II 97-99 InTIME II 97-99 ASSENT.
Antiplatelet or Anticoagulant: Do They Have the same Efficacy? University of Central Florida Deborah Andrews RN, BSN.
Linked Metabolic Abnormalities: Impaired glucose handling/ insulin resistance Atherogenic dyslipidemia Endothelial dysfunction Prothrombotic state Hemodynamic.